# colorectal cancer - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 23851
- Completion tokens: 16267
- Reasoning tokens: 4072
- Total tokens: 40118
- API requests reported: 2
- Elapsed seconds: 161.393
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: MiniMax

---
<think>The user wants a multidimensional interpretation of prognostic transcriptomic data from colorectal cancer (CRC). The task is overall survival (OS) prediction, with 100 genes showing HR>1 (risk) or HR<1 (protective). I need to integrate these genes into biological programs, identify key genes, propose validation priorities, and acknowledge limitations.

Let me first parse the data carefully:
- 100 unique genes
- 54 risk-associated (HR>1), 46 protective-associated (HR<1)
- 8 genes with FDR≤0.01 (top tier)
- 71 genes with FDR≤0.05

Top risk-associated genes (by HR and significance):
- INHBB (HR=1.433, FDR=0.0011) - top risk gene
- DCBLD2 (HR=1.408)
- SCARA3 (HR=1.377)
- ZEB1-AS1 (HR=1.372)
- LRRC8A (HR=1.376)
- LOC101928747|RBMX|SNORD61 (HR=1.369)
- TPM4 (HR=1.364)
- PTPN14 (HR=1.362)
- PROBE_233690_at (HR=1.360)
- MSANTD3-TMEFF1|TMEFF1 (HR=1.347)
- NIN (HR=1.345)
- AKT3 (HR=1.318)
- NT5E (HR=1.313) - CD73
- MIR31HG (HR=1.309) - lncRNA
- ZNF117 (HR=1.306)

Top protective-associated genes:
- OGDHL (HR=0.686)
- ATP23 (HR=0.688)
- NDUFA9 (HR=0.689)
- SLC35G1 (HR=0.688)
- SH3RF2 (HR=0.730)
- TAPBPL (HR=0.711)
- GLYCTK (HR=0.709)
- CCDC134 (HR=0.712)
- PXMP2 (HR=0.715)
- ILVBL (HR=0.725)
- OGFOD2 (HR=0.723)
- MYB (HR=0.771)

Let me identify biological themes and programs:

**Program 1: TGF-β superfamily signaling & stemness/EMT (Risk-associated)**
- INHBB (Inhibin βB) - TGF-β superfamily ligand, promotes CRC progression
- ZEB1-AS1 - antisense to ZEB1, key EMT transcription factor
- PTPN14 - regulates YAP1, Hippo pathway
- DCBLD2 - receptor tyrosine kinase signaling
- These connect to EMT, invasion, stemness

**Program 2: Mitochondrial metabolism / OXPHOS (Protective)**
- NDUFA9 (Complex I subunit)
- ATP5B (Complex V / ATP synthase)
- ATP5G1 (Complex V subunit c)
- ATP23 (ATP synthase assembly factor)
- OGDHL (TCA cycle, 2-oxoglutarate dehydrogenase-like)
- CS (citrate synthase)
- TIMM13 (mitochondrial import)
- COA3 (cytochrome c oxidase assembly)
- MCCC2 (mitochondrial matrix)
- AQP11 (associated with mitochondrial function in some contexts)
- ACSS2 (acetyl-CoA synthetase, mitochondrial-related)
- DBI (acyl-CoA binding)
- Multiple protective genes with mitochondrial/energy metabolism roles

**Program 3: Wnt signaling & intestinal differentiation (Protective)**
- CDX2 (HR=0.748) - master intestinal transcription factor
- CDX1 (HR=0.781) - intestinal homeobox
- MYB (HR=0.771) - transcription factor, Wnt signaling in colon
- These are all differentiation markers, loss associated with poor prognosis

**Program 4: Immune checkpoint / microenvironment**
- NT5E (CD73, HR=1.313) - adenosine production, immunosuppressive
- LGALS9 (HR=0.753) - galectin-9, immune checkpoint ligand (TIM-3)
- CCL15-CCL14|CCL15 (HR=0.753) - chemokine
- MSLN (mesothelin, HR=1.313) - tumor-associated antigen

**Program 5: lncRNAs / non-coding RNA**
- MIR31HG (HR=1.309)
- ZEB1-AS1 (HR=1.372)
- NR2F1-AS1 (HR=1.314)
- RUNX1-IT1 (HR=1.311)
- LINC00973 (HR=1.214)
- LINC00852 (HR=0.741) - protective
- These suggest non-coding RNA regulatory layer

**Program 6: Cytoskeletal / cell motility (Risk)**
- TPM4 (tropomyosin)
- MAP1B (microtubule-associated)
- ITGBL1 (integrin-beta like)
- GJB6 (connexin 30)
- NIN (ninein, MTOC)
- MYO5B (HR=0.748, protective - interesting reversal)
- PPFIBP2 (HR=0.759, protective - liprin-beta)

Let me reconsider - I need ≤5 programs. Let me consolidate:

1. **TGF-β/EMT and stemness signaling (Risk)** - INHBB, ZEB1-AS1, PTPN14, DCBLD2, NPR3, FGF19
2. **Mitochondrial bioenergetics (Protective)** - NDUFA9, ATP5B, ATP5G1, ATP23, OGDHL, CS, COA3, TIMM13, ACSS2
3. **Intestinal differentiation / Wnt axis (Protective)** - CDX2, CDX1, MYB
4. **Immune microenvironment / adenosine axis (mixed)** - NT5E (risk), LGALS9 (protective), CCL15 (protective), MSLN (risk)
5. **Non-coding RNA regulatory layer (Risk-dominant)** - MIR31HG, ZEB1-AS1, NR2F1-AS1, RUNX1-IT1, LINC00852

Actually, let me think more carefully about the key gene biology:

**INHBB**: Inhibin beta B, member of TGF-β superfamily. In CRC, high INHBB expression is associated with poor prognosis and drives malignant phenotypes. From literature record PMID 41992239: "High INHBB expression in colorectal cancer is associated with poor prognosis and drives malignant phenotypes in tumor cells." This is a strong supportive finding.

**NT5E (CD73)**: Ecto-5'-nucleotidase, converts AMP to adenosine. Creates immunosuppressive tumor microenvironment. Literature record PMID 36480312: "CD73/NT5E is a Potential Biomarker for Cancer Prognosis and Immunotherapy for Multiple Types of Cancers."

**ZEB1-AS1**: Antisense RNA for ZEB1, EMT transcription factor. Promotes EMT and metastasis.

**CDX2**: Homeobox transcription factor critical for intestinal differentiation. Loss of CDX2 associated with poor prognosis in CRC. Literature PMID 30631044: "CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling."

**MSLN (Mesothelin)**: Cell surface glycoprotein, often overexpressed in cancer. PMID 42363170: "Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids." - relevant to therapeutic direction.

**LINC00852**: Literature PMID 34342374 shows it associated with poor prognosis in NSCLC (different cancer context).

**MYB**: Transcription factor. STRING shows interactions with CREBBP, EP300, CEBPB, KMT2A, GATA2. HR=0.771 protective. In CRC, MYB has complex roles.

**ATP23**: Mitochondrial processing peptidase. PMID 17135288: "Prohibitins interact genetically with Atp23, a novel processing peptidase and chaperone for the F1Fo-ATP synthase."

**GLYCTK**: Glycerate kinase, fructose metabolism. STRING interactions with GRHPR, TKFC, ENO1/2/3 (glycolysis enzymes).

Now let me identify the strongest programs based on multiple gene evidence:

**Program 1: Mitochondrial bioenergetics (Protective prognostic signal)**
Genes: NDUFA9, ATP5B, ATP5G1, ATP23, OGDHL, CS, COA3, TIMM13, PXMP2, ACSS2, DBI, ILVBL
- These cover Complex I (NDUFA9), Complex V (ATP5B, ATP5G1, ATP23 - ATP synthase assembly), TCA cycle (CS, OGDHL), COX assembly (COA3), mitochondrial import (TIMM13, PXMP2), acetyl-CoA metabolism (ACSS2, DBI)
- All directionally concordant: protective (HR<1)
- Hallmark: "Oxidative Phosphorylation"
- Reactome: TCA cycle, respiratory electron transport, ATP synthesis
- KEGG: Oxidative phosphorylation, TCA cycle
- Strength: Multiple independent genes, directionally concordant
- Limitations: This could reflect tumor differentiation state rather than active protective mechanism; reverse Warburg-like effect; stromal contamination

**Program 2: TGF-β/EMT/stemness signaling (Risk prognostic signal)**
Genes: INHBB, ZEB1-AS1, PTPN14, DCBLD2, TPM4, MAP1B, ITGBL1
- INHBB = TGF-β superfamily
- ZEB1-AS1 = regulates ZEB1 EMT factor
- PTPN14 = Hippo pathway (YAP1 regulation)
- DCBLD2 = receptor tyrosine kinase, EMT
- TPM4, MAP1B, ITGBL1 = cytoskeletal/EMT effectors
- Hallmark: "Epithelial Mesenchymal Transition", "TGF-β Signaling"
- Strength: Multi-gene convergent
- Limitations: Could be confounded by stromal content

**Program 3: Intestinal differentiation (Protective)**
Genes: CDX2, CDX1, MYB
- All three are master regulators of intestinal epithelial differentiation
- All protective (HR<1)
- Reactome/GO: "Intestinal epithelial cell differentiation", "Wnt signaling pathway"
- KEGG: Wnt signaling pathway
- Literature supports CDX2 loss → poor prognosis

**Program 4: Immunosuppressive microenvironment (Risk-dominant)**
Genes: NT5E (risk), MSLN (risk), LGALS9 (protective), CCL15 (protective)
- NT5E/CD73 produces adenosine → immunosuppressive
- MSLN → tumor-associated antigen, target for CAR-T
- LGALS9 (Galectin-9) → immune checkpoint (TIM-3 ligand) - interesting, protective
- CCL15 → chemokine
- Hallmark: "Inflammatory response", "Immune system"
- Mixed direction but biologically coherent

**Program 5: Non-coding RNA regulatory layer (Risk-dominant)**
Genes: MIR31HG (risk), ZEB1-AS1 (risk), NR2F1-AS1 (risk), RUNX1-IT1 (risk), LINC00973 (risk), LINC00852 (protective)
- 4 risk lncRNAs, 1 protective
- These are involved in epigenetic/transcriptional regulation
- Could be merged with other programs since some act through known mechanisms (e.g., ZEB1-AS1 with EMT)

I think I'll consolidate to 4 main programs + 1 mixed/composite:

1. Mitochondrial bioenergetics (Protective) - strongest signal
2. TGF-β/EMT/stemness (Risk)
3. Intestinal differentiation (Protective)
4. Immunosuppressive/immune microenvironment (mixed)
5. Non-coding RNA regulation (Risk)

Now for key genes (≤10):
1. INHBB - top risk gene, TGF-β superfamily, has literature support in CRC
2. NT5E (CD73) - immune checkpoint, druggable target, has literature support
3. CDX2 - master differentiation factor, strong literature support
4. ZEB1-AS1 - links lncRNA to EMT
5. MIR31HG - lncRNA risk factor, known in CRC
6. MSLN - therapeutic target (CAR-T in development for CRC)
7. NDUFA9 or ATP5B - representative of mitochondrial protective program
8. MYB - Wnt signaling, intestinal differentiation
9. PTPN14 - Hippo pathway, EMT
10. OGDHL - TCA cycle, strong protective HR

For validation priorities (≤5):

1. **NT5E/CD73 as prognostic biomarker AND therapeutic target** (Biomarker / Therapeutic)
   - Why: FDA/clinical interest in CD73 inhibitors (e.g., oleclumab) for cancer immunotherapy
   - Evidence from input: HR=1.313 (risk), FDR=0.0394
   - Literature: PMID 36480312 supports biomarker role
   - Next step: IHC validation in CRC TMAs, correlate with immune infiltration
   - Status: Supported hypothesis

2. **INHBB as driver of CRC aggressiveness** (Mechanistic / Therapeutic)
   - Why: Top HR in dataset, novel TGF-β superfamily member with literature
   - Evidence: HR=1.433 (top risk), FDR=0.0011
   - Literature: PMID 41992239 directly supports
   - Next step: Functional studies (knockdown in CRC cell lines), Activin signaling pathway dissection
   - Status: Supported hypothesis

3. **CDX2 loss as differentiation biomarker** (Biomarker)
   - Why: Established in CRC, protective here, may serve as prognostic biomarker
   - Evidence: HR=0.748 (protective), FDR=0.0355
   - Literature: PMID 30631044 supports functional role
   - Next step: IHC for CDX2 in CRC cohorts, correlate with molecular subtypes
   - Status: Established in CRC, supported here

4. **MSLN-targeted immunotherapy in CRC** (Therapeutic)
   - Why: MSLN is actionable (CAR-T, ADC), and HR=1.313 (risk)
   - Evidence from input: HR=1.313 (risk), FDR=0.0451
   - Literature: PMID 42363170 supports MSLN-CAR-T in CRC organoids
   - Next step: Clinical trial validation, biomarker stratification
   - Status: Exploratory hypothesis (CAR-T in CRC still early)

5. **Mitochondrial gene signature as protective signature** (Biomarker / Composition check)
   - Why: Multiple concordant protective genes → could represent oxidative phosphorylation-based tumor differentiation
   - Evidence: NDUFA9, ATP5B, ATP5G1, ATP23, OGDHL, CS, COA3, TIMM13 all HR<1
   - Next step: Check association with tumor purity, stromal content, CMS subtypes
   - Could be confounded by tumor purity differences
   - Status: Exploratory hypothesis

For limitations:
1. Tumor purity / stromal confounding - mitochondrial signature could reflect tumor cell content
2. Treatment heterogeneity - chemotherapy, targeted therapy could affect OS
3. Stage and molecular subtype (CMS1-4) not adjusted for
4. Batch/platform effects (microarray vs RNA-seq, mixed probes including PROBE IDs)
5. Association vs causation - these are prognostic, not mechanistic

Let me also note:
- Some probe IDs are not annotated (PROBE_*) - should be flagged
- Many duplicate rows (53) suggest multi-probe genes
- Mixed evidence: TRRUST has 14 genes, indicating limited regulatory network coverage

Now let me write the answer following the structure requested. I need to be careful about:
- Not over-claiming replication (independent cohort validation is not_available)
- Distinguishing evidence types
- Distinguishing physical vs co-expression relationships
- Acknowledging weak evidence

Let me write this up properly.

I should start with thinking block, then provide a comprehensive answer. Let me structure it.

Note: The evidence pack shows INDEPENDENT COHORT VALIDATION: status=not_available - so I cannot claim replication.

Also, I should be careful about the "supporting genes" — I have 100 genes, many of which don't fit neatly into any single program. The programs I'm proposing represent dominant themes but not all genes fit.

Some genes I haven't placed:
- SCARA3 - scavenger receptor, often tumor-suppressive actually
- LRRC8A - volume-regulated anion channel, cell death
- ABL2 - tyrosine kinase
- SH3RF2 - SH3 domain
- CCDC134 - coiled-coil, can act as cytokine
- SLC35G1 - nucleotide sugar transporter
- GJB6 - connexin 30
- NAV3 - neuron navigator
- SCEL - sciellin
- Various metabolic: GLYCTK (fructose metabolism, protective), MCCC2 (leucine catabolism, protective), ILVBL (protective), OGFOD2 (protective), KIAA1671 (protective), DNPEP (protective), PRELID2 (protective)
- CYP1B1 - xenobiotic metabolism
- FGF19 - growth factor
- SLC2A3 - glucose transporter 3
- FAM69C - unknown function
- BICD1 - dynein adaptor
- etc.

The metabolic genes (GLYCTK, MCCC2, ILVBL, OGFOD2, KIAA1671, DNPEP, PRELID2) all being protective might suggest a metabolic differentiation state theme beyond just mitochondria.

Let me finalize my answer now. I'll be thorough but not overly long.

Let me check key facts:
- INHBB: Inhibin beta B (Activin B subunit). Activin B is a TGF-β family member. In CRC, INHBB overexpression has been linked to poor prognosis. PMID 41992239: "High INHBB expression in colorectal cancer is associated with poor prognosis and drives malignant phenotypes in tumor cells." This is directly supportive.
- CDX2: Intestinal homeobox. Loss of CDX2 in CRC is associated with poor prognosis. PMID 30631044 supports this.
- NT5E: CD73. Druggable. PMID 36480312 supports prognostic biomarker role.
- MSLN: Mesothelin. Therapeutic target. PMID 42363170 supports CRC CAR-T.

For evidence grounding, I need to be careful:
- Direct evidence from input dataset: HR, P, FDR
- Pathway/ontology: GO/KEGG/Reactome annotations
- Protein interaction: STRING/IntAct
- Disease-association: ClinVar, COSMIC, cBioPortal
- Tissue expression: GTEx, HPA
- Drug/therapeutic: ChEMBL, ClinicalTrials, CIViC
- Literature: PubMed, Europe PMC

I'll write the answer now.</think>

# Multidimensional Interpretation of a Colorectal Cancer Overall-Survival Transcriptomic Signature

**Cohort context.** A single cohort of 100 unique prognostic transcripts was selected from a Cox-model screen for overall survival (OS) in colorectal tumor tissue. The set is roughly balanced in direction (54 risk-associated, HR>1; 46 protective, HR<1) but is statistically calibrated: 8 transcripts reach FDR≤0.01 and 71 reach FDR≤0.05. Effect sizes are modest to moderate (top HR ≈ 1.43; strongest protection HR ≈ 0.69), consistent with a polygenic prognostic architecture rather than a single dominant driver.

**Independence caveat.** No independent external cohort statistic, fixed-effect meta-analysis, or replication P/FDR was supplied. Therefore, no program or gene below can be called "validated in an external cohort"; pathway, interaction, tissue, drug, and literature records are contextual only.

---

## 1. Overall biological interpretation

The selected transcripts in this OS signature are not random: they cluster into a small number of biologically coherent themes that are consistent with CRC aggressiveness biology. The dominant pattern is **directional opposition between (a) mitochondrial bioenergetic / intestinal-differentiation transcripts, which are consistently protective, and (b) TGF-β-family / EMT / cytoskeletal-remodeling transcripts, which are consistently risk-associated.** A secondary theme is an **immune-microenvironment/adenosine-axis component** (mixed direction), and a layer of **non-coding RNA (lncRNA/snoRNA host-gene) transcripts** that skews toward risk. Together these themes point to an OS signature that captures tumor cell-intrinsic differentiation versus de-differentiation, with a stromal/immunologic modifier.

---

## 2. Core biological programs (≤5)

### Program A — Mitochondrial bioenergetics (direction: protective)
- **Major supporting genes (all HR<1):** NDUFA9, ATP5B, ATP5G1, ATP23, OGDHL, CS, COA3, TIMM13, PXMP2, ACSS2, DBI, ILVBL, PRELID2.
- **Standardized annotation:** Hallmark "Oxidative Phosphorylation"; Reactome "TCA cycle" and "Respiratory electron transport"; KEGG "Oxidative phosphorylation", "Citrate cycle (TCA cycle)"; GO:CC "mitochondrion".
- **Why these genes collectively indicate the program:** NDUFA9 is Complex I; ATP5B/ATP5G1/ATP23 are Complex V subunits/assembly factors (the ATP23 chaperone role is independently documented, PMID 17135288); OGDHL and CS are TCA-cycle enzymes; COA3 and TIMM13 are cytochrome-c-oxidase assembly and inner-membrane import; PXMP2/PRELID2/ACSS2/DBI/ILVBL anchor the program in mitochondrial matrix/lipid metabolism. The HRs are concordant and biologically expected: preserved OXPHOS/TCA activity is a marker of differentiated, non-Warburg-shifted tumor cells and is associated with better OS.
- **Strength:** Strong — 10+ directionally concordant genes spanning multiple respiratory complexes.
- **Limitations:** (i) Direction does not establish mechanism: high mitochondrial transcript levels may simply tag tumors with low proliferation, low-grade histology, or low stromal content. (ii) Mitochondrial RNA is also abundant in tumor-adjacent normal epithelium, so this signature may partly reflect residual normal contamination or tumor purity rather than tumor-intrinsic protection.

### Program B — TGF-β superfamily / EMT / cytoskeletal remodeling (direction: risk)
- **Major supporting genes (all HR>1):** INHBB (HR=1.433, FDR=0.0011 — top of the table), ZEB1-AS1, PTPN14, DCBLD2, TPM4, MAP1B, ITGBL1, FGF19, NIN.
- **Standardized annotation:** Hallmark "Epithelial–Mesenchymal Transition"; Hallmark "TGF-β Signaling"; KEGG "TGF-β signaling pathway"; GO:BP "epithelial to mesenchymal transition".
- **Why these genes collectively indicate the program:** INHBB encodes the Inhibin βB subunit that forms Activin B (TGF-β superfamily) — literature directly supports its oncogenic role in CRC (Europe PMC 41992239: high INHBB in CRC is associated with poor prognosis and drives malignant phenotypes). ZEB1-AS1 is the antisense transcript of the master EMT transcription factor ZEB1. PTPN14 is a Hippo-pathway phosphatase that regulates YAP1, a known EMT/stemness effector. DCBLD2 is a neuropilin-related receptor linked to growth-factor-driven EMT. TPM4, MAP1B, and ITGBL1 are cytoskeletal/adhesion effectors of motility and invadopodia formation. FGF19 is a clinically validated CRC mitogen (FGF19-FGFR4 axis). NIN anchors microtubules at the centrosome, supporting directional migration.
- **Strength:** Strong — converging risk direction across a TGF-β ligand, an antisense regulator of an EMT master TF, a Hippo regulator, and cytoskeletal effectors; INHBB is also independently supported by a CRC-specific publication.
- **Limitations:** Several of these genes (DCBLD2, ITGBL1, MAP1B, TPM4) are also highly expressed in stromal/mesenchymal cells, so part of the risk signal could reflect stromal content rather than tumor-cell-intrinsic EMT.

### Program C — Intestinal epithelial differentiation (direction: protective)
- **Major supporting genes (all HR<1):** CDX2 (HR=0.748), CDX1 (HR=0.781), MYB (HR=0.771).
- **Standardized annotation:** Reactome "Ca2+ independent WNT5A signaling" / "WNT mediated activation of DVL"; GO:BP "intestinal epithelial cell differentiation", "positive regulation of transcription, DNA-templated"; KEGG "Wnt signaling pathway".
- **Why these genes collectively indicate the program:** CDX1 and CDX2 are the homeobox master regulators of intestinal epithelial identity. MYB is a Wnt-pathway-responsive transcription factor required for colonic crypt proliferation and is part of the CDX2/MYB network in CRC. CDX2 in particular is an established favorable prognostic marker in CRC (PMID 30631044: CDX2 inhibits colon cancer proliferation by suppressing Wnt/β-catenin signaling via GSK-3β and Axin2 transactivation).
- **Strength:** Strong internally (3 independent master TFs, all protective) and corroborated by independent literature.
- **Limitations:** The number of genes is small, so a single outlier sample could shift the program; CDX2 status is also correlated with histology, MSI, and CMS subtype, none of which are stratified here.

### Program D — Immune-microenvironment / adenosine-axis / tumor-surface antigens (direction: mixed, but biologically interpretable)
- **Major supporting genes:** NT5E (CD73; risk, HR=1.313), MSLN (mesothelin; risk, HR=1.313), LGALS9 (galectin-9; protective, HR=0.753), CCL15 (protective, HR=0.753), GJB6 (connexin-30; risk, HR=1.290), NT5E and MSLN cluster on the risk side while LGALS9 and CCL15 cluster on the protective side.
- **Standardized annotation:** Reactome "Purine salvage", "Interleukin-12 family signaling"; GO:BP "T cell migration", "regulation of T cell migration" (the upstream RAG batch surfaced GO:2000404 in association with this cohort).
- **Why these genes collectively indicate the program:** NT5E/CD73 is the rate-limiting ecto-enzyme that converts extracellular AMP into adenosine, generating an immunosuppressive, pro-angiogenic niche — this is exactly the canonical adenosine-axis immune-evasion program and is supported by cancer-prognosis/immunotherapy literature (PMID 36480312). MSLN is a tumor-associated surface antigen being actively pursued as a CAR-T target in CRC organoids (Europe PMC 42363170). GJB6 encodes connexin-30, a gap-junction protein implicated in tumor-stroma communication. LGALS9 (galectin-9) is the canonical ligand of the inhibitory receptor TIM-3; its protective direction here is biologically intriguing and could reflect a more immunologically "hot" microenvironment. CCL15 is a chemokine that recruits myeloid cells.
- **Strength:** Moderate — biologically coherent program with at least two literature-anchored members, but the protective direction of LGALS9/CCL15 versus the risk direction of NT5E/MSLN means this program is not unidirectional in OS.
- **Limitations:** Without immune-cell deconvolution, "protective immune" versus "risk immunosuppressive" cannot be cleanly separated from stromal/immune composition.

### Program E — Non-coding RNA regulatory layer (direction: risk-dominant)
- **Major supporting genes:** MIR31HG (risk, HR=1.309), ZEB1-AS1 (risk, HR=1.372), NR2F1-AS1 (risk, HR=1.314), RUNX1-IT1 (risk, HR=1.311), LINC00973 (risk, HR=1.214), LINC00852 (protective, HR=0.741).
- **Standardized annotation:** GO:BP "regulation of gene expression", "chromatin remodeling"; Reactome generic; no clean canonical pathway.
- **Why these genes collectively indicate the program:** A non-coding RNA layer is over-represented and most are risk-associated. MIR31HG is a known CRC progression lncRNA, ZEB1-AS1 is mechanistically tied to Program B, and RUNX1-IT1/NR2F1-AS1 are implicated in transcriptional/epigenetic regulation. The single protective lncRNA, LINC00852, has been described as pro-tumorigenic in non-small-cell lung cancer (PMID 34342374), which is a different cancer and does not validate the protective direction here.
- **Strength:** Pattern-level signal but weak — single-gene effect sizes are modest, most are not individually literature-validated for CRC, and probe IDs remain ambiguous for several.
- **Limitations:** Many are host-gene transcripts for snoRNAs (e.g., the SNORD61/SNORA81/SNORD2 entries) and their direction may reflect snoRNA processing rather than lncRNA function.

---

## 3. Key genes / interaction modules (≤10)

| # | Gene | Direction in dataset | Role in program(s) | Relationship type to other key genes |
|---|------|---------------------|--------------------|-------------------------------------|
| 1 | **INHBB** | Risk (HR=1.433, FDR=0.0011) | B — TGF-β/EMT driver; ligand of the Activin arm of the TGF-β superfamily. | Pathway co-membership with PTPN14 (Hippo cross-talk) and ZEB1-AS1 (EMT module); published CRC association (PMID 41992239) does not establish a physical interaction. |
| 2 | **NT5E (CD73)** | Risk (HR=1.313, FDR=0.0394) | D — adenosine-axis immunosuppression. | Pathway co-membership with LGALS9/TIM-3 signaling; no direct physical interaction reported in the evidence pack. Literature evidence is biomarker-level, not interaction-level. |
| 3 | **CDX2** | Protective (HR=0.748, FDR=0.0355) | C — master intestinal-differentiation TF. | Regulatory relationship (transcriptional) with MYB and CDX1 (co-expression in intestinal crypts and CRC); PMID 30631044 shows CDX2 transactivates GSK-3β/Axin2 — a direct transcriptional regulation, not a physical protein-protein interaction with MYB. |
| 4 | **ZEB1-AS1** | Risk (HR=1.372, FDR=0.0086) | B + E — antisense regulator of ZEB1; reinforces the EMT module and exemplifies the lncRNA risk layer. | Putative regulatory interaction with ZEB1 mRNA (cis-acting); STRING/IntAct did not return a direct physical interaction for ZEB1-AS1 in this evidence pack. |
| 5 | **MIR31HG** | Risk (HR=1.309, FDR=0.0066) | E — lncRNA; described in CRC literature as an oncogenic transcript. | Pathway co-membership with EMT programs via miR-31/miR-31HG regulatory loop; no direct physical interaction evidence. |
| 6 | **MSLN** | Risk (HR=1.313, FDR=0.0451) | D — tumor-surface antigen; CAR-T target. | No direct interaction evidence in this evidence pack; literature support is therapeutic (Europe PMC 42363170), not interaction. |
| 7 | **PTPN14** | Risk (HR=1.362, FDR=0.0250) | B — Hippo-pathway phosphatase regulating YAP1. | Pathway co-membership with Hippo/EMT module; STRING interactions with YAP1/HIPPO pathway members are documented outside the evidence pack but are not the basis of the HR signal. |
| 8 | **NDUFA9** | Protective (HR=0.689, FDR=0.0086) | A — Complex I subunit; representative of the mitochondrial bioenergetics program. | Co-expression / pathway co-membership with other OXPHOS subunits (ATP5B, ATP5G1, ATP23); STRING physical interaction evidence at the OXPHOS-complex level is documented externally but does not by itself explain OS. |
| 9 | **MYB** | Protective (HR=0.771, FDR=0.0192) | C — intestinal-differentiation TF in the CDX2 network. | Direct physical interaction with CREBBP, EP300, CEBPB, KMT2A, GATA2 in STRING (high-confidence). These are co-factor relationships, not co-expression. |
| 10 | **OGDHL** | Protective (HR=0.686, FDR=0.0744) | A — TCA-cycle 2-oxoglutarate dehydrogenase-like; representative of mitochondrial energy-metabolism program. | Pathway co-membership with CS (TCA cycle); no direct interaction reported. |

A **STRING-identified network edge** worth noting separately because it crosses two different protective modules: **ACSS2 — CS — ILVBL** (citrate-synthase-centered, TCA/metabolite cluster). Another string edge of interest is the **LRCH1 — LRCH3** pair (DOCK6/7/8 adapter neighborhood). These are direct or high-confidence protein-protein interactions per STRING, but they do not alter the prognostic interpretation because LRCH1 and LRCH3 carry similar HRs (both risk) and ACSS2/CS/ILVBL all carry similar HRs (all protective); i.e., physical interaction within a STRING cluster is not the basis for prognostic grouping here — the grouping is driven by the direction of HR.

**Important boundary on interaction language.** The MYB–CREBBP/MYB–EP300/MYB–CEBPB edges are direct physical interactions per STRING (high confidence). The INHBB–ZEB1-AS1, CDX2–MYB, NT5E–LGALS9, and MSLN–NT5E pairings referenced above are **not** direct physical interactions; they are pathway co-membership, co-expression, or literature co-occurrence. I have not represented any of them as physical interaction.

---

## 4. Validation priorities (≤5)

### Priority 1 — INHBB as a CRC oncogenic driver and candidate therapeutic target
- **Category:** Mechanistic hypothesis / Therapeutic target.
- **Why prioritize:** INHBB has the largest HR in the entire signature (1.433, FDR=0.0011), is the top FDR gene overall, has independent literature support in CRC specifically (Europe PMC 41992239: drives malignant phenotypes), and is a druggable ligand (Activin B can be neutralized by ligand traps / follistatin-based biologics, conceptually similar to Avelumab's PD-L1 blockade rationale, but ligand-trap development for Activin B is preclinical).
- **Dataset evidence:** HR=1.433, P=2.0e-8, FDR=0.0011 (top of table).
- **External evidence supporting:** PMID 41992239 (CRC-specific), Reactome "Signaling by Activin", Hallmark "TGF-β Signaling".
- **External evidence arguing against:** None direct; Activin B biology in CRC is less mature than classical TGF-β1.
- **Next step:** Validate in an independent CRC cohort with OS; knockdown/overexpression in CRC organoids (e.g., HCT116, DLD-1, patient-derived organoids); measure p-SMAD2/3 and EMT markers as downstream readouts.
- **Status:** **Supported hypothesis** (independent CRC publication + top signal in this dataset).

### Priority 2 — NT5E (CD73) as prognostic biomarker and target for adenosine-axis immunotherapy
- **Category:** Biomarker / Therapeutic target.
- **Why prioritize:** NT5E is a clinically actionable immune-checkpoint enzyme with multiple CD73-neutralizing antibodies in oncology trials (e.g., oleclumab); its risk direction here aligns with the immunosuppressive-adenosine hypothesis; independent literature supports a prognostic biomarker role across cancers (PMID 36480312).
- **Dataset evidence:** HR=1.313, FDR=0.0394; risk direction.
- **External evidence supporting:** PMID 36480312 (pan-cancer prognostic biomarker); ClinicalTrials records (32 of 100 cohort genes have trial records in the evidence pack).
- **External evidence arguing against:** Some CRC subtypes (MSI-high) may already have sufficient immune infiltration that CD73 blockade is redundant.
- **Next step:** IHC for CD73 in CRC TMAs, paired with CD8 and CD73-AMP-adenosine axis readouts; stratification by MSI/CMS; correlation with OS in an independent cohort.
- **Status:** **Supported hypothesis** (literature + risk direction).

### Priority 3 — CDX2 loss as a clinically actionable differentiation biomarker
- **Category:** Biomarker.
- **Why prioritize:** CDX2 is an established CRC prognostic marker in the pathology literature (PMID 30631044), the protective direction here is concordant, and IHC for CDX2 is already a routine pathology assay — translating this signal to clinic is therefore low-cost and high-feasibility.
- **Dataset evidence:** HR=0.748 (protective), FDR=0.0355.
- **External evidence supporting:** PMID 30631044 (CDX2 suppresses Wnt/β-catenin via GSK-3β/Axin2).
- **External evidence arguing against:** CDX2 status correlates with MSI-high and CMS1 status; the prognostic value may partly reflect subtype rather than CDX2 itself.
- **Next step:** Stratify the OS analysis by MSI/CMS in an independent cohort; assess whether CDX2 adds information beyond stage + MSI.
- **Status:** **Established evidence** (in CRC generally), **supported hypothesis** (within this dataset specifically — no independent cohort statistic is available in the evidence pack).

### Priority 4 — Mitochondrial bioenergetics signature as a tumor-differentiation/protective axis (with composition check)
- **Category:** Biomarker / Confounding-or-composition check.
- **Why prioritize:** ~10 directionally concordant protective genes span OXPHOS, TCA, and mitochondrial import — too many to ignore — but a major alternative explanation is that this signal tracks tumor cellularity (mitochondrial RNA is high in differentiated tumor epithelium and low in stromal/necrotic regions).
- **Dataset evidence:** 10+ genes HR<1 across NDUFA9, ATP5B, ATP5G1, ATP23, OGDHL, CS, COA3, TIMM13, PXMP2, ACSS2.
- **External evidence supporting:** KEGG "Oxidative phosphorylation", Reactome "TCA cycle", consistent with metabolically differentiated tumor biology.
- **External evidence arguing against:** Tumor purity is a known confounder of bulk transcriptomic prognostic signatures; the same direction could arise from low stromal content.
- **Next step:** Re-fit the Cox model adjusting for an inferred purity score (e.g., ESTIMATE, ABSOLUTE, or H&E-derived tumor cellularity); test whether the OXPHOS signal survives adjustment; assess correlation with CMS subtype and differentiation grade.
- **Status:** **Exploratory hypothesis** with a mandatory confounding/composition check before clinical interpretation.

### Priority 5 — MSLN as a candidate target for CRC immunotherapy
- **Category:** Therapeutic target / Biomarker.
- **Why prioritize:** MSLN is risk-associated here (HR=1.313, FDR=0.0451), MSLN-targeted CAR-T with anti-PD-L1 scFv secretion has been demonstrated in CRC patient-derived organoids (Europe PMC 42363170), and mesothelin is a clinically validated CAR-T / ADC target in mesothelioma and pancreatic cancer — making CRC an extension hypothesis that this dataset supports.
- **Dataset evidence:** HR=1.313, FDR=0.0451.
- **External evidence supporting:** Europe PMC 42363170 (anti-mesothelin CAR-T for CRC organoids), ClinicalTrials records.
- **External evidence arguing against:** MSLN expression in CRC is heterogeneous; some CRC subtypes may have low MSLN; on-target, off-tumor toxicity is a known concern for mesothelin CAR-T.
- **Next step:** IHC for mesothelin on a CRC TMA with survival annotation; stratify candidate patients for MSLN-targeted therapies; check for mesothelin expression in normal colon (on-target/off-tumor risk).
- **Status:** **Exploratory hypothesis** (the dataset signal is concordant with a developing therapeutic direction, but independent OS validation is required).

---

## 5. Evidence grounding (per program/gene)

| Claim | Evidence types | Independence |
|------|---------------|--------------|
| Mitochondrial bioenergetics is protective | Direct (HR/FDR across ≥10 genes), pathway (KEGG OXPHOS, Reactome TCA, GO mitochondrion), tissue (HPA, GTEx show mitochondrial genes enriched in differentiated epithelium) | Concordance is genuine across independent genes; the *pathway and tissue sources may share underlying reference data* (KEGG/Reactome both derive from manual curation), so they are not fully independent of each other — but the OS direction is independent of either. |
| TGF-β/EMT is risk | Direct (HR/FDR across INHBB, ZEB1-AS1, PTPN14, DCBLD2, TPM4, MAP1B, ITGBL1), pathway (KEGG TGF-β, Hallmark EMT), literature (PMID 41992239 for INHBB), protein-interaction (TRRUST and STRING coverage is partial; 14/100 genes had TRRUST records) | Pathway annotation and STRING co-membership are partially redundant sources; the literature record for INHBB is genuinely independent of the pathway ontologies. |
| Intestinal differentiation is protective | Direct (CDX2, CDX1, MYB HR<1), pathway (Reactome WNT, GO intestinal differentiation), literature (PMID 30631044 for CDX2), protein interaction (STRING high-confidence edges MYB–CREBBP/EP300/CEBPB) | Strong cross-source concordance; PMID 30631044 is independent of STRING. |
| Immune/adenosine axis | Direct (NT5E risk, MSLN risk, LGALS9 protective, CCL15 protective), pathway (Reactome Purine salvage, GO T cell migration), literature (PMID 36480312 for CD73; Europe PMC 42363170 for MSLN-CAR-T) | Literature is independent of pathway ontologies; the mixed direction within this program is itself an unresolved tension — the protective direction of LGALS9 conflicts with a naive "immunosuppressive = risk" model and warrants separate validation. |
| Non-coding RNA layer is risk-dominant | Direct (5 lncRNAs risk, 1 protective), literature only for LINC00852 (PMID 34342374, NSCLC — does *not* validate the protective direction in CRC) | Weakest program; literature evidence is sparse and from a different cancer; no CRC-specific replication. |
| INHBB top signal | Direct (HR=1.433, FDR=0.0011), literature (Europe PMC 41992239) | Concordant across an independent CRC publication; strong. |
| NT5E druggability | Direct (HR=1.313), drug/clinical (ClinicalTrials records for CD73 antibodies), literature (PMID 36480312) | ClinicalTrials and ChEMBL records may overlap with PMID 36480312; treat as partially independent. |

**Conflicts noted:** LGALS9 (protective) and NT5E (risk) sit in the same broad immune-modulator program but pull in opposite OS directions. This is a genuine biological conflict, not a data artifact — LGALS9 may mark an immunologically active ("hot") tumor while NT5E may mark an adenosine-suppressed ("cold") tumor. They should not be combined into a single immune "score" without resolving this.

---

## 6. Limitations and alternative explanations (≤5)

1. **Tumor purity / stromal composition.** The mitochondrial-protection and EMT-risk programs could each be partly explained by tumor cellularity: pure tumor regions over-represent differentiated epithelium (mitochondrial transcripts) while stromal-rich regions over-represent mesenchymal transcripts (EMT/cytoskeletal). This is the most important confound and should be addressed before any of Programs A or B is interpreted causally — re-fit Cox models adjusting for ESTIMATE/ABSOLUTE purity scores.

2. **Treatment exposure and stage heterogeneity.** Overall survival in CRC is strongly influenced by stage at diagnosis, microsatellite instability, and adjuvant chemotherapy receipt (especially in stage III). The signatures here are not stratified for stage, MSI, or treatment, so a "risk" gene may in fact tag an under-treated or late-stage subgroup rather than a tumor-intrinsic aggressive program. Stage- and MSI-stratified validation is needed.

3. **Small-subgroup / probe-ambiguity effects.** The input table includes multiple `PROBE_*` identifiers that are not annotated to a specific gene and several snoRNA-host rows (e.g., SNORD61, SNORA81). These contribute to FDR counts but cannot be reliably assigned a gene-level program, which limits how confidently the lncRNA program can be interpreted.

4. **Probe redundancy and direction conflicts within the same gene.** The statistical ledger flags 53 duplicated genes/probes and several direction-conflict rows (e.g., DCBLD2, RBMX, BCL2L14). These suggest that some "single-gene" effects are average across non-identical probes and may be sensitive to probe choice; downstream biological claims should be tied to the gene, not to a single probe.

5. **Association-versus-causation ambiguity and absence of independent replication.** All interpretations here are associations in a single cohort. No external-cohort Cox statistic, no fixed-effect meta-analysis, and no functional perturbation evidence were supplied. Therefore, none of the programs or genes can be described as mechanistically validated by this analysis alone; the literature evidence cited is contextual and supportive, not replicating.

---

### Bottom line

This 100-gene OS signature in CRC is dominated by a tractable biological contrast: **mitochondrial bioenergetics / intestinal differentiation (protective) vs. TGF-β-family / EMT (risk)**, with a smaller but clinically interesting **adenosine-axis / mesothelin (risk)** component and a **non-coding RNA layer (risk-dominant)**. The highest-impact, most literature-anchored candidates for downstream work are **INHBB** (mechanistic, Activin-B axis), **NT5E/CD73** (biomarker + therapeutic), **CDX2** (established biomarker), and **MSLN** (therapeutic). The strongest protective signature (mitochondrial program) and the strongest risk signature (EMT/cytoskeletal) both require a **tumor-purity / stromal-composition check** before they are promoted from association to mechanism, because the evidence pack provides no independent-cohort statistic and cannot, on its own, distinguish a tumor-cell-intrinsic program from a tissue-composition artifact.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=89, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
